IDEAS home Printed from https://ideas.repec.org/a/spr/aphecp/v17y2019i3d10.1007_s40258-018-0451-1.html
   My bibliography  Save this article

A Payer Perspective of the Hospital Inpatient Additional Care Costs of Antimicrobial Resistance in France: A Matched Case–Control Study

Author

Listed:
  • Mehdi Touat

    (Paris-Saclay University)

  • Marion Opatowski

    (Paris-Saclay University)

  • Christian Brun-Buisson

    (Paris-Saclay University)

  • Kristel Cosker

    (AP-HP University Hospitals Pitié Salpêtrière-Charles Foix)

  • Didier Guillemot

    (Paris-Saclay University)

  • Jerome Salomon

    (Ministry of Social Affairs and Health)

  • Philippe Tuppin

    (CNAM (National Health Insurance))

  • Gregoire de Lagasnerie

    (Social Security Directorate, Ministry of Social Affairs and Health)

  • Laurence Watier

    (Paris-Saclay University)

Abstract

Background and Objective Antimicrobial resistance (AMR) has become one of the biggest threats to global public health given its association with mortality, morbidity and cost of health care. However, little is known on the economic burden of hospitalization attributable to AMR from a public health insurance perspective. We assessed the excess costs to the French public health insurance system attributable to AMR infections in hospitals. Methods Bacterial infectious disease-related hospitalizations were extracted from the National health data information system for all stays occurring in 2015. Bacterial infections, strains, and microbial resistance were identified by specific French ICD-10 codes. Information about health care expenditure, co-morbidities and demographic characteristics (i.e. gender, age) are provided. We used a matched case–control approach to determine the excess of reimbursements paid to stays with AMR compared to stays with an infection without resistance. Cases and controls were matched on gender, age, Charlson comorbidity index, category of infection, infection as principal diagnosis (two classes), microorganism and hospital status. The overall AMR cost was extrapolated to stays with AMR and excluded from the sample (multiple infections), and a second extrapolation was performed to consider stays with unknown resistance status. Results The final sample included 52,921 matched-pairs (98.2% cases). Our results suggest that AMR overall cost reached EUR109.3 million in France with a mean of EUR1103 per stay; extrapolation to the entire database shows that the overall cost could potentially reach EUR287.1 million if all cases would be identified. The mean excess length of hospital stay attributable to AMR was estimated at 1.6 days. Conclusion AMR causes substantial cost burden in France for the public health insurance. Our study confirms the need to reinforce programs to prevent AMR infection and thereby reduce their economic burden.

Suggested Citation

  • Mehdi Touat & Marion Opatowski & Christian Brun-Buisson & Kristel Cosker & Didier Guillemot & Jerome Salomon & Philippe Tuppin & Gregoire de Lagasnerie & Laurence Watier, 2019. "A Payer Perspective of the Hospital Inpatient Additional Care Costs of Antimicrobial Resistance in France: A Matched Case–Control Study," Applied Health Economics and Health Policy, Springer, vol. 17(3), pages 381-389, June.
    • Handle: RePEc:spr:aphecp:v:17:y:2019:i:3:d:10.1007_s40258-018-0451-1
    DOI: 10.1007/s40258-018-0451-1
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40258-018-0451-1
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40258-018-0451-1?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Sabine Vogler & Katharina Habimana & Manuel Alexander Haasis & Stefan Fischer, 2024. "Pricing, Procurement and Reimbursement Policies for Incentivizing Market Entry of Novel Antibiotics and Diagnostics: Learnings from 10 Countries Globally," Applied Health Economics and Health Policy, Springer, vol. 22(5), pages 629-652, September.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:aphecp:v:17:y:2019:i:3:d:10.1007_s40258-018-0451-1. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.